Efficacy of Recombinant Human Endostatin plus Neoadjuvant Chemotherapy for Osteosarcoma and Its Influence on Serum VEGF and MMP-9 Levels

Table 2

Clinical efficacy.

	CR	PR	SD	PD	Overall response rate
Control group (n = 65)	20 (30.8)	22 (33.8)	13 (20.0)	10 (15.4)	42 (64.6)
Combination group (n = 76)	38 (50.0)	26 (34.2)	8 (10.5)	4 (5.3)	64 (84.2)
χ ^2	8.8773				7.2091
	0.0310				0.0073